A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab.

Trial Profile

A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Dactolisib (Primary) ; Trastuzumab (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 26 Sep 2012 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 31 May 2012 Interim results will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012), according to a Novartis media release.
    • 22 Feb 2012 Additional trial locations identified as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top